DelveInsight Reports Over 70 Companies Developing Treatments for Dry AMD

DelveInsight has released its "Dry Age-Related Macular Degeneration Pipeline Insight, 2026" report, offering a comprehensive analysis of the therapeutic landscape for Dry Age-Related Macular Degeneration (Dry AMD).

The report identifies more than 70 companies actively developing over 75 drugs for Dry AMD. The pipeline includes candidates in various stages of development, from early research to late-stage clinical trials. Each drug profile details its mechanism of action, clinical trial status, and regulatory progress.

Dry AMD is a leading cause of vision loss, affecting the macula and progressively diminishing central vision. While current management focuses on slowing disease progression, the extensive pipeline indicates significant efforts to find new treatment options. The report segments these developments by product type, stage, route of administration, and molecule type.

In addition to active projects, the report also details inactive pipeline products. This comprehensive overview aims to provide stakeholders with a clear understanding of the current and future outlook for Dry AMD treatments, highlighting key players and developmental trends in the global market.